Eprosartan
| Code | Size | Price |
|---|
| TAR-T2531L-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T2531L-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Eprosartan is a competitive and reversible angiotensin II receptor antagonist. It also used for the treatment of high blood pressure. The drug acts on the renin-angiotensin system to decrease total peripheral resistance. It blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation and it inhibits sympathetic norepinephrine production, further reducing blood pressure.
CAS:
133040-01-4
Formula:
C23H24N2O4S
Molecular Weight:
424.52
Purity:
0.98
SMILES:
CCCCc1ncc(C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O
References
1. Takezako T, Unal H, Karnik SS, Node K. Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism. Pharmacol Res. 2017 Sep;123:40-50. doi: 10.1016/j.phrs.2017.06.013. Epub 2017 Jun 23. Review. PubMed PMID: 28648738; PubMed Central PMCID: PMC5567726.
2. Yang R, Luo Z, Liu Y, Sun M, Zheng L, Chen Y, Li Y, Wang H, Chen L, Wu M, Zhao H. Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450. Curr Drug Metab. 2016;17(7):681-91. Review. PubMed PMID: 27216792.
3. Castilla-Guerra L, Fernandez-Moreno Mdel C. Chronic Management of Hypertension after Stroke: The Role of Ambulatory Blood Pressure Monitoring. J Stroke. 2016 Jan;18(1):31-7. doi: 10.5853/jos.2015.01102. Epub 2015 Dec 17. Review. PubMed PMID: 26687120; PubMed Central PMCID: PMC4747066.
4. Zaiken K, Hudd TR, Cheng JW. A review of the use of angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications. Ann Pharmacother. 2013 May;47(5):686-93. doi: 10.1345/aph.1R273. Epub 2013 Apr 12. Review. PubMed PMID: 23585649.